Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dobutamine on hepatic blood flow during goal-directed hemodynamic therapy
2020-005412-21Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dobutamine in Perioperative cardiovascular instability (PCVI) and Ischemic hepatitis, sponsored by Ghent University Hospital. Primary endpoints: Change in portal hepatic blood flow during goal-directed hemodynamic therapy, Change in arterial hepatic blood flow during goal-directed hemodynamic therapy and 2 more. Started Feb 2021; status: completed.
02
Drugs
dobutamine
03
Conditions
Perioperative cardiovascular instability (PCVI)Ischemic hepatitis
Beyond the preview
Go deeper on 2020-005412-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005412-21.